TG Therapeutics (TGTX) Continuing to Drive on All Cylinders; Roth Affirms 'Focus Pick' Rating
Tweet Send to a Friend
Roth Capital reaffirms TG Therapeutics, Inc. (Nasdaq: TGTX) with a Focus Pick rating and $33 price target following Q2 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
